

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

05 AUG 12 PM 3: 02

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Williams & Jensen, PLLC			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1155 21st Street, NW Suite 300 City Washington State/Zip (or Country) DC 20036			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Barbara W. Bonfiglio			5. Senate ID # 41454-924
Telephone 202-659-8201			E-mail (optional)
7. Client Name <input type="checkbox"/> Self AstraZeneca Pharmaceuticals Group(formerly Zeneca)			6. House ID # 30771057

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) ☒ OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbyi

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$100,000.00</u> <div style="text-align: right; font-size: small;">Income (nearest \$20,000)</div> Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ <div style="text-align: right; font-size: small;">Expenses (nearest \$20,000)</div> 14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of <input type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6033 of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(c) of the Internal Revenue Code

Signature _____ Date 08/14/2005

Printed Name and Title Barbara W. Bonfiglio - Attorney Page _____

Registrant Name: Williams & Jensen, PLLC

Client Name: AstraZeneca Pharmaceuticals Group(formerly Zeneca)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Lynch, Karina V.	
Olsen, George G.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Bonnie Ann Hildner

Signature  Date 08/14/2005

Printed Name and Title Barbara W. Bonfiglio - Attorney Pag

Registrant Name: Williams & Jensen, PLLCClient Name: AstraZeneca Pharmaceuticals Group(formerly Zeneca)

Item	Description	Data
16	Lobbying Issues	Medicare drug benefit Reimportation Average wholesale price payments Medical records privacy Drug pricing legislation Bioterrorism Hatch Waxman reform Pharmaceutical pricing Direct to consumer advertising Medicaid reform Drug safety Payments for cancer drugs

